Other European Operations
Otsuka Map
Otsuka Pharmaceutical Europe has established businesses in 10 of the European markets. In the other 22 European countries*, Otsuka’s European operation manages its business, selling our products—ABILIFY®, Abilify Maintena® and Samsca®—through a mixture of partnerships and distributors.   These European markets offer significant opportunities to expand and grow Otsuka’s business in Europe.  *Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Iceland, Ireland, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia and Slovenia. 

Global TB Programme

Global TB in Europe
Otsuka Pharmaceutical Company’s (OPC) global tuberculosis programme exemplifies the company’s creative ingenuity and patient-centred approach. We have worked relentlessly for more than 30 years to find a new treatment option for patients suffering from multidrug-resistant tuberculosis (MDR-TB). Remaining focused on this dream, European regulatory approval for a novel compound was granted in April 2014. Otsuka Novel Products GmbH in Munich, Germany (Marketing Authorisation Holder) is working on commercial and public health strategies to improve TB care and ensure rational use of new anti-TB medications.

Date of preparation: September 2018

Reference OPSE/0818/COMS/1079